The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1449
August 18, 2014
View Complete Issue         Table of Contents 2019 
Glycerol Phenylbutyrate (Ravicti) for Urea Cycle Disorders
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Glycerol Phenylbutyrate (Ravicti) for Urea Cycle Disorders
August 18, 2014 (Issue: 1449)
The FDA has approved an oral liquid formulation of glycerol phenylbutyrate (Ravicti – Hyperion) for chronic management of patients ≥2 years old with urea cycle disorders that cannot be adequately managed by a protein- restricted diet. Sodium...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Glycerol Phenylbutyrate (Ravicti) for Urea Cycle Disorders
Article code: 1449c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.